Matthew 25 Management’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$25.5M Sell
22,000
-2,500
-10% -$2.95M 7.38% 3
2026
Q2
$29.4M Sell
24,500
-3,000
-11% -$3.07M 8.51% 3
2026
Q1
$25.3M Buy
27,500
+2,000
+8% +$2.03M 8.4% 3
2025
Q4
$27.4M Buy
25,500
+10,000
+65% +$9.6M 8.38% 4
2025
Q3
$11.8M Buy
15,500
+8,250
+114% +$6.14M 3.64% 13
2025
Q2
$5.65M Buy
+7,250
New +$5.63M 1.82% 17

Other funds holding LLY

Matthew 25 Management's LLY Position: Q3 2026 in Review

Matthew 25 Management reduced its Eli Lilly (LLY) stake by 10% in Q3 2026, selling an estimated $2.95M and leaving 22,000 shares worth $25.5M. The position accounts for 7.38% of the portfolio, ranked #3.

Matthew 25 Management first reported a position in LLY in Q2 2025 and has held it in 6 quarters since. The position peaked at $29.4M in Q2 2026. 4,106 funds tracked by Wall St. Rank hold LLY as of Q3 2026.

  • Matthew 25 Management held 22,000 shares of Eli Lilly worth $25.5M as of Q3 2026.
  • Matthew 25 Management sold 2,500 Eli Lilly shares in Q3 2026, an estimated $2.95M.
  • Eli Lilly made up 7.38% of Matthew 25 Management's portfolio in Q3 2026, its #3 holding.
  • Matthew 25 Management first reported a position in Eli Lilly in Q2 2025 and has held it in 6 quarters since.
  • Matthew 25 Management's Eli Lilly position peaked at $29.4M in Q2 2026.
  • 4,106 funds tracked by Wall St. Rank held Eli Lilly as of Q3 2026.

Based on Matthew 25 Management's 13F filing for Q3 2026, filed 10 Nov 2026.